NZ336838A - A method of enhancing the level of perfusion of blood to a target tissue by administering an adenoviral vector encoded with an angiogenic peptide within 0.5-15 cm3 of the tissue - Google Patents

A method of enhancing the level of perfusion of blood to a target tissue by administering an adenoviral vector encoded with an angiogenic peptide within 0.5-15 cm3 of the tissue

Info

Publication number
NZ336838A
NZ336838A NZ336838A NZ33683898A NZ336838A NZ 336838 A NZ336838 A NZ 336838A NZ 336838 A NZ336838 A NZ 336838A NZ 33683898 A NZ33683898 A NZ 33683898A NZ 336838 A NZ336838 A NZ 336838A
Authority
NZ
New Zealand
Prior art keywords
vector
tissue
target tissue
administered
region
Prior art date
Application number
NZ336838A
Other languages
English (en)
Inventor
Todd K Rosengart
Ronald G Crystal
Original Assignee
Cornell Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/801,352 external-priority patent/US5846225A/en
Application filed by Cornell Res Foundation Inc filed Critical Cornell Res Foundation Inc
Publication of NZ336838A publication Critical patent/NZ336838A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NZ336838A 1997-01-29 1998-01-29 A method of enhancing the level of perfusion of blood to a target tissue by administering an adenoviral vector encoded with an angiogenic peptide within 0.5-15 cm3 of the tissue NZ336838A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3660197P 1997-01-29 1997-01-29
US08/801,352 US5846225A (en) 1997-02-19 1997-02-19 Gene transfer therapy delivery device and method
US7115698P 1998-01-13 1998-01-13
PCT/US1998/001638 WO1998032859A1 (en) 1997-01-29 1998-01-29 Multiple site delivery of adenoviral vector for the induction of angiogenesis

Publications (1)

Publication Number Publication Date
NZ336838A true NZ336838A (en) 2002-04-26

Family

ID=27365066

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ336838A NZ336838A (en) 1997-01-29 1998-01-29 A method of enhancing the level of perfusion of blood to a target tissue by administering an adenoviral vector encoded with an angiogenic peptide within 0.5-15 cm3 of the tissue

Country Status (16)

Country Link
US (2) US6518255B2 (enExample)
EP (1) EP1012291B1 (enExample)
JP (1) JP2001509168A (enExample)
KR (1) KR20000070572A (enExample)
AT (1) ATE279518T1 (enExample)
AU (1) AU745409B2 (enExample)
BR (1) BR9806819A (enExample)
CA (1) CA2278621A1 (enExample)
DE (1) DE69827021T2 (enExample)
HU (1) HUP0001964A3 (enExample)
IL (1) IL131021A0 (enExample)
MX (1) MXPA99006993A (enExample)
NO (1) NO993669L (enExample)
NZ (1) NZ336838A (enExample)
PL (1) PL334902A1 (enExample)
WO (1) WO1998032859A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238673B2 (en) 1989-03-31 2007-07-03 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
ATE279518T1 (de) * 1997-01-29 2004-10-15 Cornell Res Foundation Inc An verschiedenen orten verabreichung von adenoviren-vektor zur induzierung von angiogenese
US6775574B1 (en) * 1997-11-07 2004-08-10 Medtronic, Inc. Method and system for myocardial infarction repair
US6458092B1 (en) 1998-09-30 2002-10-01 C. R. Bard, Inc. Vascular inducing implants
US6251079B1 (en) 1998-09-30 2001-06-26 C. R. Bard, Inc. Transthoracic drug delivery device
WO2000024415A2 (en) 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using trk receptor ligands
WO2000047235A2 (en) * 1999-02-10 2000-08-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of stimulating angiogenesis
US6986784B1 (en) 1999-05-14 2006-01-17 C. R. Bard, Inc. Implant anchor systems
US6440945B1 (en) * 1999-05-27 2002-08-27 Instituto Dermopatico Dell'immacolata Method of inducing angiogenesis in nonis chemic skeletal muscle
AU5624500A (en) * 1999-06-18 2001-01-09 Collaborative Group, Ltd., The Hyaluronic acid microspheres for sustained gene transfer
EP1067190A1 (en) * 1999-07-09 2001-01-10 Introgene B.V. Gene therapy for enhancing and/or inducing angiogenesis
US6855160B1 (en) 1999-08-04 2005-02-15 C. R. Bard, Inc. Implant and agent delivery device
AU6521500A (en) 1999-08-05 2001-03-05 Cornell Research Foundation Inc. Gene therapy platformed needle and method of administering therapeutic solution to a heart
FR2799465B1 (fr) * 1999-10-12 2004-02-13 Centre Nat Rech Scient Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire
KR20020049031A (ko) * 1999-11-05 2002-06-24 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 생체내 유전자 송달에 의하여 심혈관 질환을 치료하기위한 기술 및 조성물
US6329348B1 (en) * 1999-11-08 2001-12-11 Cornell Research Foundation, Inc. Method of inducing angiogenesis
US7232421B1 (en) 2000-05-12 2007-06-19 C. R. Bard, Inc. Agent delivery systems
US6508802B1 (en) 2000-05-23 2003-01-21 Cornell Research Foundation, Inc. Remote sensing gene therapy delivery device and method of administering a therapeutic solution to a heart
US7204847B1 (en) 2000-07-28 2007-04-17 C. R. Bard, Inc. Implant anchor systems
US6939540B1 (en) 2000-07-31 2005-09-06 Cornell Research Foundation, Inc. Method of enhancing bone density
JP2004505619A (ja) * 2000-08-04 2004-02-26 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 血管内皮増殖因子２
US20040009940A1 (en) * 2000-10-20 2004-01-15 Coleman Michael E. Gene delivery formulations and methods for treatment of ischemic conditions
EP1330252A4 (en) * 2000-11-01 2007-12-26 Ludwig Inst Cancer Res IN VIVO STIMULATION OF ANGIOGENIC ACTIVITY
EP1361896A2 (en) * 2001-01-23 2003-11-19 Boston Scientific Corporation Localized myocardial injection method for treating ischemic myocardium
AR027161A1 (es) 2001-05-15 2003-03-19 Bio Sidus S A Metodo para inducir la proliferacion neovascular y regeneracion tisular
US20030157064A1 (en) * 2001-11-09 2003-08-21 Pascal Neuville Chimeric promoters for controlling expression in muscle cells
JP2006514929A (ja) * 2002-11-15 2006-05-18 ジェンベク、インコーポレイティッド 冠動脈疾患の治療
JP4667451B2 (ja) 2004-04-05 2011-04-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｎｋｇ２ｄの調節
JP5855326B2 (ja) 2005-01-06 2016-02-09 ノヴォ ノルディスク アー／エス 抗ｋｉｒ組み合わせ治療および方法
RU2321631C2 (ru) * 2005-06-24 2008-04-10 Государственное учреждение Российский научный центр хирургии РАМН Неинфекционный для человека аденовирус как вектор для заместительной генной терапии нарушений ангиогенеза, обеспечивающий эффективный синтез ангиогенина человека в трансфецированных клетках млекопитающих, способ индукции ангиогенеза, способ лечения ишемической болезни, композиция для индукции ангиогенеза и лечения ишемической болезни
US7751883B2 (en) 2006-04-25 2010-07-06 Eugenio Picano System and method for promoting coronary angiogenesis
US9598673B2 (en) * 2006-05-19 2017-03-21 Creative Medical Health Treatment of disc degenerative disease
US8983570B2 (en) * 2007-03-27 2015-03-17 Cardiovascular Biotherapeutics, Inc. Therapeutic angiogenesis for treatment of the spine
US11224635B2 (en) 2007-03-27 2022-01-18 Venturis Thereuptics, Inc. Therapeutic angiogenesis for treatment of the spine and other tissues
AU2008319053B2 (en) 2007-11-01 2012-04-26 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
US8088108B2 (en) * 2009-08-22 2012-01-03 Joseph Wayne Kraft Rapid local anesthesia injection cone
US8409147B2 (en) * 2009-08-22 2013-04-02 Joseph Wayne Kraft Rapid local anesthesia linear injection device
CN102740894B (zh) * 2009-08-28 2015-07-15 克利夫兰临床医学基金会 用于治疗缺血组织的sdf-1递送
US20150206302A1 (en) * 2012-08-30 2015-07-23 Emory University Systems, methods and computer readable storage media storing instructions for integrating fluoroscopy venogram and myocardial images
HRP20240623T1 (hr) * 2013-01-17 2024-08-02 Medizinische Hochschule Hannover Faktor 1 protein za uporabu u liječenju ili prevenciji bolesti
US11421229B2 (en) 2015-02-20 2022-08-23 Baylor College Of Medicine p63 inactivation for the treatment of heart failure
CN110381976A (zh) 2016-12-05 2019-10-25 努里塔斯有限公司 包括肽wkdeagkplvk的组合物
EP3329930A1 (en) 2016-12-05 2018-06-06 Nuritas Limited Pharmaceuctical compositions
US20240115732A1 (en) * 2019-10-09 2024-04-11 Xylocor Therapeutics, Inc. Epicardial Delivery of Gene Therapy
WO2024233783A1 (en) 2023-05-09 2024-11-14 Cornell University Expression cassette coding for vascular endothelial growth factor

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US510413A (en) 1893-12-12 Drainage-tube
US2551902A (en) 1948-09-10 1951-05-08 Arthur Schaffer Dehorning fluid ejector
US2670673A (en) 1950-07-17 1954-03-02 Joyce A Gordon Fluid injecting device
US3467096A (en) 1966-04-12 1969-09-16 Ferrell S Horn Multiple hypodermic syringe arrangement
FR1584474A (enExample) 1968-02-20 1969-12-26
US3572336A (en) 1968-04-30 1971-03-23 Daniel R Hershberg Syringe
US4150669A (en) 1977-03-16 1979-04-24 Alvaro Latorre Apparatus for effecting and enhancing an erection
US4167179A (en) 1977-10-17 1979-09-11 Mark Kirsch Planar radioactive seed implanter
US5335670A (en) 1986-04-18 1994-08-09 Henry Fishman Allergy testing method and apparatus
JPS6438100A (en) 1987-07-31 1989-02-08 Toray Industries Vascular endothelial cell growth factor
JPH02117698A (ja) 1988-10-27 1990-05-02 Toray Ind Inc 血管内皮細胞成長因子
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
JPH02279698A (ja) 1989-04-20 1990-11-15 M K Medical:Kk 血管内皮細胞成長因子及びその製造方法
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
DE69024261T2 (de) 1989-05-24 1996-07-18 Merck & Co Inc Reinigung und Charakterisierung eines von einem Glioma abstammenden Wachstumsfaktors
US5219739A (en) * 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
JPH03178996A (ja) 1989-12-06 1991-08-02 Makoto Goto 成長因子
US6228844B1 (en) * 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
EP0476983B1 (en) 1990-09-21 2000-03-15 Merck & Co. Inc. Vascular endothelial cell growth factor II
EP0506477B1 (en) 1991-03-28 1999-06-23 Merck & Co. Inc. Vascular endothelial cell growth factor C subunit
US5244460A (en) 1991-11-27 1993-09-14 The United States Of America As Represented By The Department Of Health And Human Services Method to foster myocardial blood vessel growth and improve blood flow to the heart
EP0550296A3 (en) 1991-11-28 1993-12-29 Terumo Corp Vascular endothelial cells growth factor
US5290258A (en) 1992-07-27 1994-03-01 Genesis Industries, Inc. Syringe for administering sequentially multiple doses of a medicament
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
DK0751992T3 (da) 1994-03-08 2006-03-06 Human Genome Sciences Inc Karendotelvækstfaktor 2
US5851806A (en) * 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5417683A (en) 1994-07-13 1995-05-23 Shiao; I-Shen Mini-graft hair implanting device for implanting multiple clumps of hair follicles at one time
EP0804076A4 (en) * 1994-10-19 1998-10-21 Genetic Therapy Inc GENTHERAPY THROUGH SIMULTANEOUS AND REPEATED ADMINISTRATION OF ADENOVIRUS AND IMMUNE SUPPRESSIVES
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
JP3178996B2 (ja) 1995-08-24 2001-06-25 沖電気工業株式会社 カード処理装置及びカード送り速度の制御方法
US6121246A (en) 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
ATE279518T1 (de) * 1997-01-29 2004-10-15 Cornell Res Foundation Inc An verschiedenen orten verabreichung von adenoviren-vektor zur induzierung von angiogenese
US5846225A (en) 1997-02-19 1998-12-08 Cornell Research Foundation, Inc. Gene transfer therapy delivery device and method
JP3371331B2 (ja) * 1998-12-14 2003-01-27 セイコーエプソン株式会社 インクジェット式記録ヘッドおよびその製造方法

Also Published As

Publication number Publication date
EP1012291A1 (en) 2000-06-28
KR20000070572A (ko) 2000-11-25
US6518255B2 (en) 2003-02-11
HUP0001964A2 (hu) 2000-10-28
AU6253098A (en) 1998-08-18
BR9806819A (pt) 2000-05-09
DE69827021D1 (de) 2004-11-18
EP1012291B1 (en) 2004-10-13
WO1998032859A1 (en) 1998-07-30
PL334902A1 (en) 2000-03-27
AU745409B2 (en) 2002-03-21
US20030103943A1 (en) 2003-06-05
NO993669D0 (no) 1999-07-28
CA2278621A1 (en) 1998-07-30
MXPA99006993A (es) 2005-06-01
IL131021A0 (en) 2001-01-28
HUP0001964A3 (en) 2002-01-28
ATE279518T1 (de) 2004-10-15
NO993669L (no) 1999-09-27
US20010041679A1 (en) 2001-11-15
DE69827021T2 (de) 2005-02-24
JP2001509168A (ja) 2001-07-10

Similar Documents

Publication Publication Date Title
EP1012291B1 (en) Multiple site delivery of adenoviral vector for the induction of angiogenesis
Mack et al. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart
Tio et al. Intramyocardial gene therapy with naked DNA encoding vascular endothelial growth factor improves collateral flow to ischemic myocardium
Lopez et al. Angiogenic potential of perivascularly delivered aFGF in a porcine model of chronic myocardial ischemia
Freedman et al. Therapeutic angiogenesis for coronary artery disease
US6057300A (en) Methods for treating cancers and restenosis with p21
JP3961019B2 (ja) 遺伝子転移媒介の血管形成療法
EP1017421B1 (en) Use of adenoviral vectors expressing VEGF or PDGF FOR HEALING TISSUE DEFECTS AND INDUCING HYPERVASCULARITY IN MAMMALIAN TISSUE
US6329348B1 (en) Method of inducing angiogenesis
Funatsu et al. Therapeutic angiogenesis in the ischemic canine heart induced by myocardial injection of naked complementary DNA plasmid encoding hepatocyte growth factor
EP1142590A1 (en) Gene therapy for diabetic ischemic disease
EA019099B1 (ru) Способ направленной доставки трансгена в миокард пациента с ишемией миокарда
US20030228283A1 (en) Preventing secondary lymphedema with VEGF-D DNA
US20050191278A1 (en) Coronary artery disease treatment
JP2002527492A (ja) ＣＴＬＡ４Ｉｇまたは抗ＣＤ４０ＬをコードするＤＮＡを含有するリポソームによる外傷（すなわち移植片拒絶）の治療
JP2022551911A (ja) 遺伝子治療の心外膜送達
Lutter et al. Biological bypass in cardiovascular surgery
US20080095835A1 (en) Methods for treating cancers and restenosis with P21
HK1008979B (en) Gene transfer-mediated angiogenesis therapy

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)